Table 4.
Details of Anti-VEGF Therapy for Initial Age-related Macular Degeneration Treatment, 2011–2018
| Year | Cases Treated Using Anti-VEGF Therapy (%) | Initial Anti-VEGF Treatment (%) |
||
|---|---|---|---|---|
| Ranibizumab | Aflibercept | Pegaptanib | ||
| 2011 | 14 107 (100) | 13 743 (97.4) | - | 364 (2.6) |
| 2012 | 19 435 (100) | 18 652 (96.0) | 306 (1.6) | 477 (2.4) |
| 2013 | 26 702 (100) | 15 070 (56.5) | 11 304 (42.3) | 328 (1.2) |
| 2014 | 33 120 (100) | 18 111 (54.7) | 14 792 (44.7) | 217 (0.6) |
| 2015 | 34 039 (100) | 12 873 (37.8) | 20 978 (61.6) | 188 (0.6) |
| 2016 | 33 799 (100) | 9908 (29.3) | 23 763 (70.3) | 128 (0.4) |
| 2017 | 35 811 (100) | 10 944 (30.6) | 24 751 (69.1) | 116 (0.3) |
| 2018 | 35 967 (100) | 10 867 (30.2) | 25 011 (69.5) | 89 (0.3) |
| Total | 232 980 (100) | 110 168 (47.3) | 120 905 (51.9) | 1907 (0.8) |
VEGF = vascular endothelial growth factor.